FDA approved Zogenix Inc.’s Zohydro ER, finding that the single-entity extended-release hydrocodone product, the first to clear the agency, offers an important therapeutic option to treat pain.
A Schedule II controlled substance, Zohydro is indicated for the management of pain severe enough to require daily, around-the-clock, long-term treatment and for which alternative treatment options are inadequate